Pathologic findings in patients with anaphylaxis with a clonal mast-cell disorder
| Patient . | Sex . | Age at study, y . | Tryptase, ng/mL . | CD25+ MC . | 816D>V c-kit mutation* . | Aberrant MC morphology . |
|---|---|---|---|---|---|---|
| 1 | F | 46 | 7.92 | + | + | + |
| 2 | F | 44 | 21.5 | + | + | + |
| 3 | F | 31 | 128 | + | + | + |
| 4 | M | 45 | 12.7 | + | − | + |
| 5 | M | 42 | 8.11 | + | ND | + |
| Patient . | Sex . | Age at study, y . | Tryptase, ng/mL . | CD25+ MC . | 816D>V c-kit mutation* . | Aberrant MC morphology . |
|---|---|---|---|---|---|---|
| 1 | F | 46 | 7.92 | + | + | + |
| 2 | F | 44 | 21.5 | + | + | + |
| 3 | F | 31 | 128 | + | + | + |
| 4 | M | 45 | 12.7 | + | − | + |
| 5 | M | 42 | 8.11 | + | ND | + |
None of the patients had cutaneous mastocytosis or mast-cell clusters fulfilling the major WHO diagnostic criterion for systemic mastocytosis. MC indicates mast cells; M, male; F, female; +, present; −, not present; and ND, not determined.
Mutational analysis was carried out in CD25+ sorted cells in patients 1 through 3, and unsorted bone marrow mononuclear cells in patient 4.